Literature DB >> 12738113

Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.

Eric Knudtson1, Michael Para, Hillary Boswell, Patty Fan-Havard.   

Abstract

BACKGROUND: Antiretroviral therapy is associated with serious adverse events. We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation. CASE: A 26-year-old primigravida presented with a fever of 40.2C, urticarial rash, and icteric sclera 6 weeks after starting a nevirapine-containing antiretroviral regimen. Eosinophils, serum creatinine, bilirubin, and liver enzymes were markedly elevated, and abnormal coagulation studies were noted on admission. Serology testing was negative for viral hepatitis and microbiologic cultures were negative for growth. Abnormal laboratory findings at discharge resolved within 4 months after discontinuation of antiretroviral agents and systemic corticosteroid therapy.
CONCLUSION: Our case suggests the need for close monitoring of liver and renal function after initiation of nevirapine-containing antiretroviral regimens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738113     DOI: 10.1016/s0029-7844(02)02620-0

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.

Authors:  Debika Bhattacharya; Amita Gupta; Camlin Tierney; Sharon Huang; Marion G Peters; Tsungai Chipato; Frances Martinson; Neaka Mohtashemi; Dingase Dula; Kathy George; Nahida Chaktoura; Karin L Klingman; Devasena Gnanashanmugam; Judith S Currier; Mary G Fowler
Journal:  Clin Infect Dis       Date:  2021-04-26       Impact factor: 9.079

Review 2.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

Review 3.  Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.

Authors:  Zygimantas C Alsauskas; Raj Kiran Medapalli; Michael J Ross
Journal:  Expert Opin Pharmacother       Date:  2011-01-21       Impact factor: 3.889

4.  A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons.

Authors:  Chen Ren; Patty Fan-Havard; Natalia Schlabritz-Loutsevitch; Yonghua Ling; Kenneth K Chan; Zhongfa Liu
Journal:  Biomed Chromatogr       Date:  2010-07       Impact factor: 1.902

Review 5.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.

Authors:  Weerawat Manosuthi; Nopphanath Chumpathat; Achara Chaovavanich; Somnuek Sungkanuparph
Journal:  BMC Infect Dis       Date:  2005-08-24       Impact factor: 3.090

7.  Acute kidney injury in patients with human immunodeficiency virus infection.

Authors:  J Prakash; T Gupta; S Prakash; S S Rathore; S Sunder
Journal:  Indian J Nephrol       Date:  2015 Mar-Apr

8.  Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients.

Authors:  David Brandariz; Alex Smithson; Vanesa Anton-Vazquez
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jul-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.